Cover Image
市場調查報告書

自我施打注射劑 2020年

Self-administered Injectables to 2022

出版商 Greystone Research Associates 商品編碼 310074
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
自我施打注射劑 2020年 Self-administered Injectables to 2022
出版日期: 2015年09月01日 內容資訊: 英文
簡介

預測高齡化將增加確診為慢性疾病患者數量。為了減輕這個趨勢造成金融、醫療基本設備的影響,公共部門及管理護理組織預測將重視自己施打的治療法,對建立更有效率患者自我施打給藥方法及裝置的關注度高升。

本報告涵括以患者自我施打為對象的注射劑市場,提供您目前市售注射劑,需求促進要素與成長展望,自我施打注射劑設備的主要選擇要素與市場發展的課題,市場現狀及市場領導,自我施打注射器·注射器的供應商與其產品活動,產業策略及企業聯盟,經濟,技術及法規要素的影響等分析。

摘要整理

注射劑市場力學

  • 注射劑開發的發展
  • 自我施打的擴大
  • 市場成長的促進要素
  • 藥物自我施打的需求因素

注射劑設備的選擇標準

  • 人因工程/人體工學
  • 冷凍乾燥藥物·藥物重組
  • 注射器安全性/尖頭保護
  • 拋棄式藥管

自我施打注射劑:設備

  • 填充完畢注射器 (預填充式注射器:PFS)
    • 玻璃製PFS
    • 塑膠製PFS
    • 事前填充可能PFS
  • 自動注射器
    • 可重複使用 (回收) 自動注射器
    • 拋棄式自動注射器
    • 不定量給藥自動注射器
  • 筆型注射器
    • 筆型平台的標準化
    • 自訂筆設計
    • 雙心腔型筆
  • 無針注射器 (NFI)

自我施打注射劑:疾病市場區隔分析

  • 過敏性反應
  • 抗發炎
  • 抗凝固
  • 不孕治療
  • 造血劑
  • C型肝炎
  • 荷爾蒙療法/補充
  • 胰島素/血糖管理
  • 多發性硬化症
  • 骨質疏鬆症

自我施打品牌藥產品分析·市場資料

  • 阿朴嗎啡
  • 細胞聚落刺激因子
  • Erythropoietins
  • 促濾泡素
  • 融合蛋白品質
  • 荷爾蒙
  • 干擾素
  • 胰島素
  • GLP-1 受體促效劑
  • 其他血糖管理注射劑
  • 生長激素
  • Sumatriptans
  • TNF抑制劑

市場要素

  • 法規要素與風險
  • 可用性·患者體驗
  • 管理護理·醫療經濟學
  • 自訂設備設計·品牌設定

企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: SJR373T

Increases in life expectancy are expected to result in a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in administration methods and devices that are patient-friendly and cost-effective. For self administered injectables, human engineering and user ergonomics are essential attributes that impact critical patient issues such as safety and patient compliance. While designers have acquired many powerful design tools during the past decade - tools that include 3D CAD design software and high performance materials, design team have been increasingly relying on classic end user research to define the design targets for their projects related to self-administered injectables to 2020.

What You Will Learn

  • What are the currently marketed injectable drugs intended for patient self administration?
  • What are the therapeutic demand drivers for self administered injectables and what are the growth prospects for self administered injectable drugs?
  • What are the key device selection factors and market development issues for self administered injectables?
  • What doses the current self administered injectables market look like, who are the market leaders, and what will this market look like in 2022?
  • What companies supply syringes and injectors designed for patient self administration, and what are their product activities, business strategies, and corporate alliances and affiliations?
  • How important are pharma-device alliances and design partnerships in the self administered injectables market segment?
  • What is the impact of economic, technology, and regulatory factors?

Table of Contents

Summary of Contents

Executive Summary

  • Injectable Drug Market Dynamics
  • Evolution in Injectable Drug Development
  • The Growth of Self Administration
  • Market Drivers
  • Drug Self-Administration Demand Factors
  • Injectable Drug Device Selection Criteria
  • Human Engineering/Ergonomics
  • Lyophilized Drugs & Drug Reconstitution
  • Syringe Safety/Sharps Protection
  • Disposable Drug Cartridges
  • Self Administered Injectables - Device Classes & Devices
  • Prefilled Syringes (PFS)
  • Glass PFS
  • Plastic PFS
  • Prefillable PFS
  • Autoinjectors
  • Reusable Autoinjectors
  • Disposable Autoinjectors
  • Variable Dose Autoinjectors
  • Pen Injectors
  • Standardized Pen Platforms
  • Custom Pen Design
  • Dual Chamber Pens
  • Needle-free Injectors (NFI)
  • Self Administered Injectables - Disease Segment Analysis
  • Anaphylaxis
  • Anti-Inflammatory
  • Anticoagulants
  • Fertility
  • Hematopoietics
  • Hepatitis C
  • Hormone Therapy/Replacement
  • Insulins/Glycemic Control
  • Multiple Sclerosis
  • Osteoporosis

Self Administered Branded Product Analysis & Market Data

  • Apomorphine
  • Colony Stimulating Factors
  • Erythropoietins
  • Follitropins
  • Fusion Proteins
  • Hormones
  • Interferons
  • Insulins
  • GLP-1 Receptor Agonists
  • Other Glycemic Control Injectables
  • Somatropins
  • Sumatriptans
  • TNF Inhibitors
  • Market Factors
  • Regulatory Factors and Risks
  • Ease-of-Use and the Patient Experience
  • Managed Care & Healthcare Economics
  • Custom Device Designs & Branding

Company Profiles

Back to Top